Echocardiographic parameters at baseline and during epoprostenol treatment
| Baseline, n (SD) | Epoprostenol therapy, n (SD) | |
|---|---|---|
| n, number of patients; PR, pulmonary valve regurgitation; Vmax, maximal velocity. | ||
| Right ventricular function | ||
| Normal | 7 | 11 |
| Mildly impaired | 17 | 13 |
| Moderately impaired | 13 | 12 |
| Severely impaired | 2 | 3 |
| Tricuspid regurgitation | ||
| None | 2 | 0 |
| Trivial | 3 | 9 |
| Mild | 30 | 18 |
| Moderate | 3 | 11 |
| Severe | 1 | 1 |
| Vmax tricuspid valve, m/s | 4.6 (0.9) | 4.2 (0.8) |
| (complete envelope) | 34 | 36 |
| Pulmonary regurgitation | ||
| None | 16 | 18 |
| Trivial | 7 | 6 |
| Mild | 13 | 14 |
| Moderate | 3 | 1 |
| Severe | 0 | 0 |
| End diastolic PR velocity, m/s | 2.9 (0.6) | 2.8 (0.5) |
| (complete envelope) | 16 | 12 |